You are here: Industry Insights > Lynparza

News List

Lynparza, Bevacizumab Trial Meets Primary Endpoint for Advanced Ovarian Cancer americanpharmaceuticalreview
August 19, 2019
AstraZeneca and Merck announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting ...
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer worldpharmanews
August 16, 2019
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer.
AstraZeneca's cancer meds Lynparza, Imfinzi cruise toward blockbuster-land fiercepharma
July 28, 2019
AstraZeneca’s oncology portfolio put on another good show, with anti-PD-L1 Imfinzi and Merck & Co.-shared PARP inhibitor Lynparza now on track to cross the blockbuster line for the first time in 2019.
Lynparza has been approved for BRCA-mutated advanced ovarian cancer europeanpharmaceuticalreview
June 24, 2019
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
Lynparza approved in EU and Japan for BRCAm ovarian cancer pharmaceutical-technology
June 20, 2019
Intermediate magnification micrograph of a low malignant potential mucinous ovarian tumour. Credit: Nephron.
Lynparza bags EU approval for RCA-mutated advanced ovarian cancer pharmatimes
June 19, 2019
The data were presented on 21 October 2018, at the Presidential Symposium of the ESMO (European Society for Medical Oncology) 2018 Congress in Munich, Germany and published simultaneously online in The New England Journal of Medicine.
Lynparza reduces PFS in germline BRCA-mutated pancreatic cancer pharmaceutical-technology
June 05, 2019
AstraZeneca and Merck have announced that Lynparza (olaparib) demonstrated significant improvement in progression-free survival (PFS), compared to placebo, in germline BRCA-mutated metastatic .adenocarcinoma of the pancreas.
AstraZeneca’s Lynparza gets EC approval for breast cancer pharmaceutical-technology
April 23, 2019
The European Commission (EC) has approved AstraZeneca drug Lynparza (olaparib) as a monotherapy to treat locally-advanced or metastatic breast cancer in adults.
Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer pharmafile
April 11, 2019
Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by the European Commission...
Lynparza gains EU approval for type of metastatic breast cancer pharmatimes
April 11, 2019
AstraZeneca and MSD‘s Lynparza (olaparib) has been approved by the European Commission for the treatment of germline BRCA-mutated HER2-negative metastatic breast cancer.

Previous page 1 2 3 4 5 6 7 Next page